19 Sep 2016 17:00
Â
Â
Â
MaxCyte, Inc.
("MaxCyte" or the "Company")
Â
Notification of Annual General Meeting
Â
Maryland, USA - 19 September 2016: MaxCyte (LSE: MXCT), the developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, announces that formal notice and resolutions of the Company's AGM, along with the Annual Meeting Proxy Card, has been circulated to Shareholders.
Â
These documents are also available in electronic form on the Company's website: http://www.maxcyte.com/.
Â
The Annual General Meeting of Stockholders is planned to be held on 26 October 2016 at 22 Firstfield Road, Suite 110, Gaithersburg, MD 20878 USA.
Â
Â
For further information please contact:
Â
MaxCyte | +1 301 944 1660 |
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer | |
Nominated Adviser and Broker Panmure Gordon Freddy Crossley (Corporate Finance) Fabien Holler Duncan Monteith Tom Salvesen (Corporate Broking) | +44 (0) 20 7886 2500 Â |
Financial PR Advisor Consilium Strategic Communications | +44 (0)203 709 5700 maxcyte@consilium-comms.com |
Mary-Jane Elliott Chris Welsh Lindsey Neville |
Â
About MaxCyte
Â
MaxCyte is an established and revenue generating US-based developer and supplier of cell engineering products and services to biopharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology markets, which independent market analyses estimate to be, in aggregate, in excess of $35 billion in 2015. The Company's patented flow electroporation technology enables its products to deliver fast, reliable and scalable cell engineering to drive the research and clinical development of a new generation of medicines.
Â
MaxCyte's high performance platform allows transfection with any molecule or multiple molecules and is compatible with nearly all cell types, including hard-to-transfect human primary cells. It also provides a high degree of consistency and minimal cell disturbance, thereby facilitating rapid, large scale, clinical and commercial grade cell engineering in a non-viral system and with low toxicity concerns. The Company's cell engineering technology platform is CE-marked and FDA-accredited, providing MaxCyte's customers and partners with an established regulatory path.
Â
Using the unique capabilities of its technology, MaxCyte is developing CARMA, its proprietary platform in immuno-oncology, to deliver a validated non-viral approach to CAR therapies across a broad range of cancer indications, including solid tumors where existing CAR-T approaches face significant challenges.
Â
For more information visit http://www.maxcyte.com/Â